1355249-29-4

Basic information

• Product Name: ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate
• Synonyms: ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate
• CAS NO: 1355249-29-4
• Molecular Weight: 386.189
• Mol File: 1355249-29-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate(1355249-29-4)
• EPA Substance Registry System: ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate(1355249-29-4)

Safety Data

• Hazardous Substances Data: 1355249-29-4(Hazardous Substances Data)

Upstream product

• 179692-08-1 4-iodo-1H-pyrazole-3-carboxylic acid ethyl ester 
• 824-94-2 p-methoxybenzyl chloride 
• 179692-08-1 4-iodo-2H-pyrazole-3-carboxylic acid ethyl ester 
• 623-47-2 propynoic acid ethyl ester 
• 5932-27-4 ethyl 1H-pyrazole-3-carboxylate 

Downstream Products

• 1355249-30-7 C₂₀H₂₇BN₂O₅ 
• 1355249-32-9 C₂₅H₃₀N₄O₇S 
• 1355249-33-0 C₂₁H₂₆N₄O₅S 
• 1355249-34-1 C₁₆H₁₆N₄O₂S 
• 1355249-35-2 C₂₀H₁₇FN₆O₂S 
• 1355249-46-5 C₂₄H₂₈N₄O₆S 
• 1355249-47-6 C₂₂H₂₈N₄O₅S 
• 1355249-48-7 C₁₇H₁₈N₄O₂S 
• 1355249-49-8 C₂₂H₂₂N₆O₂S 
• 1355249-53-4 C₂₃H₂₆N₄O₆S 
• 1355249-54-5 C₃₂H₃₉N₅O₇S 
• 1355249-57-8 C₂₅H₂₇N₅O₃S 
• 1355249-58-9 C₂₉H₂₉N₇O₃S 
• 1355249-59-0 C₃₀H₃₁N₇O₃S 

Relevant articles and documents

PYRROLOPYRIMIDINE COMPOUND

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.

PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.